The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii ST2 isolates

References

• Bachoumas K, Lebert C, Lacherade JC, Reignier J. Community-acquired Acinetobacter baumannii pneumonia. Medecine et Maladies Infectieuses. 2015 Aug; 45(8):337–9.
   PubMed Web of Science ®Google Scholar
• Fan B, Guan J, Wang X, Cong Y. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model. PLoS One. 2016;11(6):e0157757.
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012 Jul;67(7):1607–15.
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother
   Web of Science ®Google Scholar
• Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf
   Google Scholar
• Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012 May;18(5):263–72.
   PubMed Web of Science ®Google Scholar
• Gong X, Zhang J, Su S, Fu Y, Bao M, Wang Y, et al. Molecular characterization and epidemiology of carbapenem non-susceptible Enterobacteriaceae isolated from the Eastern region of Heilongjiang Province, China. BMC Infect Dis. 2018 Aug 22;18(1):417.
   PubMedGoogle Scholar
• Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013 Aug;57(3):349–58.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents. 2015 Jun;45(6):568–85.
   PubMed Web of Science ®Google Scholar
• Kazi M, Drego L, Nikam C, Ajbani K, Soman R, Shetty A, et al. Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai. Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):467–72.
   PubMed Web of Science ®Google Scholar
• Wu W, He Y, Lu J, Lu Y, Wu J, Liu Y. Transition of blaOXA-58-like to blaOXA-23-like in Acinetobacter baumannii Clinical isolates in Southern China: an 8-year study. PLoS One. 2015;0(9):e0137174.
   Google Scholar
• Wei WJ, Yang HF. Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol. Int J Antimicrob Agents. 2017 Mar;49(3):321–6.
   PubMed Web of Science ®Google Scholar
• French GL. Bactericidal agents in the treatment of MRSA infections–the potential role of daptomycin. J Antimicrob Chemother. 2006 Dec;58(6):1107–17.
   PubMed Web of Science ®Google Scholar
• Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006 May;258(1):72–7.
   PubMed Web of Science ®Google Scholar
• Fan XC, Wang XH, Zhang JS. Detection of carbapenem gene in Acinetobacter baumannii from Eastern Heilongjiang province. Chin J Microecol. 2015;27(06):651-653, 657.
   Google Scholar
• Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 2009 Jan;16(1):35–40.
   Web of Science ®Google Scholar
• Singkham-In U, Chatsuwan T. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis. 2018 Jun;91(2):169–74.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011 Nov;
   PubMed Web of Science ®Google Scholar
• Wei W, Yang H, Hu L, Ye Y, Li J. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: In vitro and in a Galleria mellonella model. J Microbiol Immunol Infect. 2017 Dec;
   PubMedGoogle Scholar
• Cai Y, Yang J, Kan Q, Nie X, Wang R, Liang B, et al. Mutant prevention concentration of colistin alone and in combination new parameter, the susceptible breakpoint index. J Antimicrob Chemother. 2010;65:82–90.
   PubMedGoogle Scholar
• Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrob Agents Chemother. 2018 Apr;62(4):e01989–17.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002 Apr;43(4):365–85.
   PubMed Web of Science ®Google Scholar
• Petrović T, Uzunović S, Barišić I, Luxner J, Grisold A, Zarfel G, et al. Arrival of carbapenem-hydrolyzing-oxacillinases in Acinetobacter baumannii in Bosnia and Herzegovina. Infect Genet Evol. 2018 Mar;58:192–8.
   PubMed Web of Science ®Google Scholar
• Cullivan S, Brady DM, O'Callaghan DS. New Delhi metallo-beta-lactamase-producing carbapenem-resistant enterobacteriacae isolated from bronchial washings. Ir Med J. 2017 Dec 18;110(10):663.
   PubMedGoogle Scholar
• Al Atrouni A, Hamze M, Jisr T, Lemarié C, Eveillard M, Joly-Guillou M-L, et al. Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon. Int J Infect Dis. 2016 Nov;52:29–36.
   PubMed Web of Science ®Google Scholar
• Le Minh V, Thi Khanh Nhu N, Vinh Phat V, Thompson C, Huong Lan NP, Thieu Nga TV, et al. In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam. J Med Microbiol. 2015 Oct;64(10):1162–9.
   PubMedGoogle Scholar
• Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013 Aug;57(8):3990–3.
   PubMed Web of Science ®Google Scholar
• Tangden T, Karvanen M, Friberg LE, Odenholt I, Cars O. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. Infect Dis (Lond). 2017 Jul;49(7):521–7.
   PubMed Web of Science ®Google Scholar
• Lahiri S, Bangaru V, Kumar R, Rangarajan R, Pharma V, editors. A novel mechanism of action for the synergistic antibacterial activity of colistin and fosfomycin. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC) Annual Meeting, San Diego, CA; 2015.
   Google Scholar
• Madadi-Goli N, Moniri R, Bagheri-Josheghani S, Dasteh-Goli N. Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii. Iran J Microbiol. 2017 Feb;9(1):19–25.
   PubMed Web of Science ®Google Scholar
• Safarika A, Galani I, Pistiki A, Giamarellos-Bourboulis EJ. Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):317–23.
   PubMed Web of Science ®Google Scholar